HEALTHMEDPAGE TODAY
Talquetamab Regimens Boost Survival in Multiple Myeloma
A phase III trial showed that Talquetamab (Talvey) combined with daratumumab (Darzalex) and optionally pomalidomide (Pomalyst) significantly improved survival outcomes for patients with relapsed or refractory multiple myeloma compared to an active regimen.
Mentioned
Related Signal
Adjacent reporting
- B-Cell Depleter Nabs Phase III Win in Autoimmune Kidney Disease
- Breakthrough pancreatic cancer treatment could double survival time
- STAT+: At ASCO, positive data for Bristol in multiple myeloma and Pfizer in lung cancer
- Pancreatic cancer patient Ben Sasse sees 'massive' tumor reduction with experimental new drug
- Safety and efficacy of intratumoural anti-CTLA4 with intravenous anti-PD1